These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26879361)

  • 1. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire.
    Betegnie AL; Gauchet A; Lehmann A; Grange L; Roustit M; Baudrant M; Bedouch P; Allenet B
    J Rheumatol; 2016 Apr; 43(4):724-30. PubMed ID: 26879361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.
    Raghunath S; Hijjawi R; Hoon E; Shanahan EM; Goldblatt F
    Clin Rheumatol; 2019 Oct; 38(10):2699-2707. PubMed ID: 31172365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study.
    Giacomelli R; Gorla R; Trotta F; Tirri R; Grassi W; Bazzichi L; Galeazzi M; Matucci-Cerinic M; Scarpa R; Cantini F; Gerli R; Lapadula G; Sinigaglia L; Ferraccioli G; Olivieri I; Ruscitti P; Sarzi-Puttini P
    Rheumatology (Oxford); 2015 May; 54(5):792-7. PubMed ID: 25288786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.
    Kádár G; Balázs E; Soós B; Laduver A; Keszthelyi P; Szekanecz Z; Kovács L
    Clin Rheumatol; 2014 Mar; 33(3):329-33. PubMed ID: 24497172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inflammatory rheumatic diseases].
    Kellner H
    MMW Fortschr Med; 2009 Apr; 151(14):67-70; quiz 71. PubMed ID: 19504844
    [No Abstract]   [Full Text] [Related]  

  • 7. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    González-Álvaro I; Martínez-Fernández C; Dorantes-Calderón B; García-Vicuña R; Hernández-Cruz B; Herrero-Ambrosio A; Ibarra-Barrueta O; Martín-Mola E; Monte-Boquet E; Morell-Baladrón A; Sanmartí R; Sanz-Sanz J; de Toro-Santos FJ; Vela P; Román Ivorra JA; Poveda-Andrés JL; Muñoz-Fernández S; ;
    Rheumatology (Oxford); 2015 Jul; 54(7):1200-9. PubMed ID: 25526976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
    Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
    BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.
    Smolen JS; Gladman D; McNeil HP; Mease PJ; Sieper J; Hojnik M; Nurwakagari P; Weinman J
    RMD Open; 2019; 5(1):e000585. PubMed ID: 30713716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis.
    McCulley C; Katz P; Trupin L; Yelin EH; Barton JL
    J Rheumatol; 2018 Dec; 45(12):1636-1642. PubMed ID: 30219761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
    Valero M; Sánchez-Piedra C; Freire M; Colazo M; Busquets N; Meriño-Ibarra E; Rodríguez-Lozano C; Manrique S; Campos C; Sánchez-Alonso F; Castrejón I
    Arthritis Res Ther; 2023 May; 25(1):86. PubMed ID: 37217997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study.
    Kolios AGA; Hueber AJ; Michetti P; Mrowietz U; Mustak-Blagusz M; Sator PG; Reinshagen M; Wilsmann-Theis D; Gomis-Kleindienst S; Luckey U; Rössler A; Schiefke I
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):234-241. PubMed ID: 29998520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
    Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
    Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.
    Confavreux CB; Chapurlat RD
    Osteoporos Int; 2011 Apr; 22(4):1023-36. PubMed ID: 20959960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.
    Morgan C; McBeth J; Cordingley L; Watson K; Hyrich KL; Symmons DP; Bruce IN
    Rheumatology (Oxford); 2015 Oct; 54(10):1780-91. PubMed ID: 25972390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.